The relation between magnesium sulfate therapy and fetal heart rate variability

M. W. Atkinson, M. A. Belfort, George Saade, K. J. Moise

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: To determine the relation between magnesium sulfate therapy and fetal heart rate (FHR) variability. Methods: Twelve women diagnosed with preeclampsia who were to receive magnesium sulfate for seizure prophylaxis were recruited. Exclusion criteria included delivery anticipated within 2 hours, gestational age less than 28 weeks, abnormal fetal testing, fetal growth retardation, and use of illicit drugs or medications. Six grams of magnesium sulfate in 100 mL 0.9% saline was administered intravenously over 20 minutes, followed by a continuous infusion of 2 g/hour. A cardiotocogram analysis computer system was used to analyze various elements of the FHR pattern before, during, immediately after, and 60 minutes following magnesium sulfate loading. For each time interval, the basal heart rate, number of accelerations and decelerations, number of minutes of high and low variability, mean minute range variation, and the short-term (3.75-second interval) variability were measured. Results: There was a statistically significant decrease in short-term variability 60 minutes after initiation of therapy (6.7±2.0 versus 9.8±3.3 milliseconds; P=.003). Long- and medium-term variability did not change significantly after magnesium sulfate was administered. Conclusion: Although magnesium sulfate therapy was associated with an objectively measured, statistically significant decrease in short-term variability, the decrease was not clinically significant; furthermore, it was not associated with a decrease in long-term variability or in the number of accelerations measured.

Original languageEnglish (US)
Pages (from-to)967-970
Number of pages4
JournalObstetrics and Gynecology
Volume83
Issue number6
StatePublished - 1994
Externally publishedYes

Fingerprint

Magnesium Sulfate
Fetal Heart Rate
Therapeutics
Cardiotocography
Deceleration
Fetal Growth Retardation
Computer Systems
Street Drugs
Pre-Eclampsia
Gestational Age
Seizures
Heart Rate

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

The relation between magnesium sulfate therapy and fetal heart rate variability. / Atkinson, M. W.; Belfort, M. A.; Saade, George; Moise, K. J.

In: Obstetrics and Gynecology, Vol. 83, No. 6, 1994, p. 967-970.

Research output: Contribution to journalArticle

Atkinson, MW, Belfort, MA, Saade, G & Moise, KJ 1994, 'The relation between magnesium sulfate therapy and fetal heart rate variability', Obstetrics and Gynecology, vol. 83, no. 6, pp. 967-970.
Atkinson, M. W. ; Belfort, M. A. ; Saade, George ; Moise, K. J. / The relation between magnesium sulfate therapy and fetal heart rate variability. In: Obstetrics and Gynecology. 1994 ; Vol. 83, No. 6. pp. 967-970.
@article{a82d0bd8a8064dedbeacec352ad8869f,
title = "The relation between magnesium sulfate therapy and fetal heart rate variability",
abstract = "Objective: To determine the relation between magnesium sulfate therapy and fetal heart rate (FHR) variability. Methods: Twelve women diagnosed with preeclampsia who were to receive magnesium sulfate for seizure prophylaxis were recruited. Exclusion criteria included delivery anticipated within 2 hours, gestational age less than 28 weeks, abnormal fetal testing, fetal growth retardation, and use of illicit drugs or medications. Six grams of magnesium sulfate in 100 mL 0.9{\%} saline was administered intravenously over 20 minutes, followed by a continuous infusion of 2 g/hour. A cardiotocogram analysis computer system was used to analyze various elements of the FHR pattern before, during, immediately after, and 60 minutes following magnesium sulfate loading. For each time interval, the basal heart rate, number of accelerations and decelerations, number of minutes of high and low variability, mean minute range variation, and the short-term (3.75-second interval) variability were measured. Results: There was a statistically significant decrease in short-term variability 60 minutes after initiation of therapy (6.7±2.0 versus 9.8±3.3 milliseconds; P=.003). Long- and medium-term variability did not change significantly after magnesium sulfate was administered. Conclusion: Although magnesium sulfate therapy was associated with an objectively measured, statistically significant decrease in short-term variability, the decrease was not clinically significant; furthermore, it was not associated with a decrease in long-term variability or in the number of accelerations measured.",
author = "Atkinson, {M. W.} and Belfort, {M. A.} and George Saade and Moise, {K. J.}",
year = "1994",
language = "English (US)",
volume = "83",
pages = "967--970",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The relation between magnesium sulfate therapy and fetal heart rate variability

AU - Atkinson, M. W.

AU - Belfort, M. A.

AU - Saade, George

AU - Moise, K. J.

PY - 1994

Y1 - 1994

N2 - Objective: To determine the relation between magnesium sulfate therapy and fetal heart rate (FHR) variability. Methods: Twelve women diagnosed with preeclampsia who were to receive magnesium sulfate for seizure prophylaxis were recruited. Exclusion criteria included delivery anticipated within 2 hours, gestational age less than 28 weeks, abnormal fetal testing, fetal growth retardation, and use of illicit drugs or medications. Six grams of magnesium sulfate in 100 mL 0.9% saline was administered intravenously over 20 minutes, followed by a continuous infusion of 2 g/hour. A cardiotocogram analysis computer system was used to analyze various elements of the FHR pattern before, during, immediately after, and 60 minutes following magnesium sulfate loading. For each time interval, the basal heart rate, number of accelerations and decelerations, number of minutes of high and low variability, mean minute range variation, and the short-term (3.75-second interval) variability were measured. Results: There was a statistically significant decrease in short-term variability 60 minutes after initiation of therapy (6.7±2.0 versus 9.8±3.3 milliseconds; P=.003). Long- and medium-term variability did not change significantly after magnesium sulfate was administered. Conclusion: Although magnesium sulfate therapy was associated with an objectively measured, statistically significant decrease in short-term variability, the decrease was not clinically significant; furthermore, it was not associated with a decrease in long-term variability or in the number of accelerations measured.

AB - Objective: To determine the relation between magnesium sulfate therapy and fetal heart rate (FHR) variability. Methods: Twelve women diagnosed with preeclampsia who were to receive magnesium sulfate for seizure prophylaxis were recruited. Exclusion criteria included delivery anticipated within 2 hours, gestational age less than 28 weeks, abnormal fetal testing, fetal growth retardation, and use of illicit drugs or medications. Six grams of magnesium sulfate in 100 mL 0.9% saline was administered intravenously over 20 minutes, followed by a continuous infusion of 2 g/hour. A cardiotocogram analysis computer system was used to analyze various elements of the FHR pattern before, during, immediately after, and 60 minutes following magnesium sulfate loading. For each time interval, the basal heart rate, number of accelerations and decelerations, number of minutes of high and low variability, mean minute range variation, and the short-term (3.75-second interval) variability were measured. Results: There was a statistically significant decrease in short-term variability 60 minutes after initiation of therapy (6.7±2.0 versus 9.8±3.3 milliseconds; P=.003). Long- and medium-term variability did not change significantly after magnesium sulfate was administered. Conclusion: Although magnesium sulfate therapy was associated with an objectively measured, statistically significant decrease in short-term variability, the decrease was not clinically significant; furthermore, it was not associated with a decrease in long-term variability or in the number of accelerations measured.

UR - http://www.scopus.com/inward/record.url?scp=0028305498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028305498&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 967

EP - 970

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 6

ER -